Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T14:11:45.885Z.
Calculation as of: 2026-10-06T14:11:45.885Z.
Quote observation: 2026-10-06T14:10:22.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: df0d51bc4c7c4fe031789de0e9442acf829cec50a05ec95901a80cda74a8a9f3
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$3.05B
EBITDA Yield
N/A
TTM Avg
0.89%
3Y Avg
0.89%
5Y Avg
0.89%
Market Cap
$3.04B
EBITDA Yield
1.19%
TTM Avg
0.54%
3Y Avg
0.54%
5Y Avg
0.54%
Market Cap
$3.01B
EBITDA Yield
N/A
TTM Avg
127.06%
3Y Avg
127.06%
5Y Avg
127.06%
Market Cap
$2.83B
EBITDA Yield
3.66%
TTM Avg
2.99%
3Y Avg
2.18%
5Y Avg
2.18%
Market Cap
$3.40B
EBITDA Yield
3.18%
TTM Avg
4.14%
3Y Avg
4.45%
5Y Avg
4.45%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | $3.09B | N/A | N/A | N/A | N/A |
| Denali Therapeutics Inc. (DNLI)vs › | $3.05B | N/A | 0.89% | 0.89% | 0.89% |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $3.04B | 1.19% | 0.54% | 0.54% | 0.54% |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.01B | N/A | 127.06% | 127.06% | 127.06% |
| TransMedics Group, Inc. (TMDX)vs › | $2.83B | 3.66% | 2.99% | 2.18% | 2.18% |
| AtriCure, Inc. (ATRC)vs › | $2.81B | 1.28% | 1.25% | 1.25% | 1.25% |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.80B | N/A | N/A | N/A | N/A |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.40B | 3.18% | 4.14% | 4.45% | 4.45% |
| Celcuity Inc. (CELC)vs › | $3.45B | N/A | N/A | N/A | N/A |
| MBX Biosciences, Inc. Common Stock (MBX)vs › | $2.71B | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
